Peptide therapeutics: Its all in the delivery

Therapeutic Delivery

Volumn 3, Issue 8, 2012, Pages 981-996

  Grant, Marshall ^a   Leone Bay, Andrea ^a  

^a MannKind Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEXYL INSULIN MONOCONJUGATE 2; INFLUENZA VACCINE; INSULIN; INSULIN ASPART; LINAGLIPTIN; LIRAGLUTIDE; NASULIN; ORACAL; OSTORA; OXYNTOMODULIN; OXYTOCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEPTIDE YY [3-36]; PLACEBO; RECOMBINANT HUMAN INSULIN; SALCATONIN; SAXAGLIPTIN; SITAGLIPTIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; PEPTIDE;

ABDOMINAL DISCOMFORT; AREA UNDER THE CURVE; BIOAVAILABILITY; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SOLUBILITY; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOARTHRITIS; OSTEOPOROSIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; VOMITING; INSTRUMENTATION; METHODOLOGY;

DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; PEPTIDES;

EID: 84865511133     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.79     Document Type: Review

References (70)

1. Klerman EB, Adler GK, Jin M, Maliszewski AM, Brown EN. A statistical model of diurnal variation in human growth hormone. Am. J. Physiol. Endocrinol. Metab. 285(5), E1118-E1126 (2003). (Pubitemid 37296335)
2. Hindmarsh PC. The impact of hormone physiology on clinical practice with reference to two papers spanning 40 years of endocrinology. Arch. Dis. Child. 90(11), 1144-1147 (2005). (Pubitemid 41565274)
3. Frolik CA, Black EC, Cain RL et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33(3), 372-379 (2003). (Pubitemid 37103254)
4. Basu A, Man CD, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of Type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 32(5), 866-872 (2009).
5. Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28(5), 1077-1082 (2005). (Pubitemid 40616616)
6. Bolli GB, Luzio S, Marzotti S et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with Type 2 diabetes. Diabetes Obes. Metab. 13(3), 251-257 (2011).
7. Steiner S, Hompesch M, Pohl R et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 51(9), 1602-1606 (2008).
8. Salinari S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in Type 2 diabetic subjects after bariatric surgery. Diabetes Care 32(3), 375-380 (2009).
9. Lefèbvre PJ, Paolisso G, Scheen AJ, Henquin JC. Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia 30(7), 443-452 (1987). (Pubitemid 17139070)
10. Ihlo CA, Lauritzen T, Sturist J, Skyggebjerg O, Christiansen JS, Larsen T. Treatment pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart. Diabetic Med. 28(2), 230-236 (2011).
11. Wasan KM. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. 28(9), 1047-1058 (2002). (Pubitemid 35278830)
12. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20(2-3), 153-214 (2003). (Pubitemid 37237279)
13. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs. Biodrugs 19(3), 165-177 (2005).
14. Aungst BJ. Intestinal permeation enhancers. J. Pharm. Sci. 89(4), 429-442 (2000).
15. Sharma P, Varma MVS, Chawla HPS, Panchagnula R. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Il Farmaco 60(11-12), 884-893 (2005). (Pubitemid 41586262)
16. Mehta N, Erickson K, Stern W et al. Nighttime dosing with an oral calcitonin tablet significantly reduces plasma CTx-1. J. Bone Miner. Res. 24 (Suppl. 1), (2009).
17. Binkley N, Bolognese M, Sidorowicz-Bialynicka A et al. A Phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the ORACAL trial. J. Bone Miner. Res. doi:10.1002/jbmr.1602 (2012) (In Press).
18. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteroporosis with oral calcitonin. BMC Clin. Pharmacol. 8 (12) (2008).
19. Karsdal MA, Byrjalsen I, Azira M et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br. J. Clin. Pharmacol. 67(4), 413-420 (2009).
20. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin. Pharmacol. 8 (5) (2008).
21. Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with Type 2 diabetes. Diabetes Care 33(6), 1288-1290 (2010).
22. Clement S, Dandona P, Still JG, Kosutic G. Oral modified insulin (HIM2) in patients with Type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53(1), 54-58 (2004). (Pubitemid 38071936)
23. Khedkar A, Iyer H, Anand A et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in Type 2 diabetes mellitus subjects. Diabetes Obes. Metab. 12(8), 659-664 (2010).
24. Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J. Womens Health 21(2), 161-169 (2012).
25. Kalluri H, Banga AK. Transdermal delivery of proteins. AAPS PharmSciTech 12(1), 431-441 (2011).
26. Prausnitz MR, Langer R. Transdermal drug delivery. Nat. Biotechnol. 26(11), 1261-1268 (2008).
27. Patel YR. Altea Therapeutics Transdermal PassPort™ system: freedom from insulin injections for superior diabetes management. In: Drug Delivery in Diabetes: Making Effective Treatment Tolerable. Furness G (Ed.). ONdrugDelivery Ltd, Newtimber, UK, 4-7 (2006).
28. Shalom SI, Kenan Y, Matsumoto T, Neer R. Repetitive rapid delivery of pharmacologically-active hPTH 1-34 across human skin without injection. Presented at: 30th ASMBR Annual Meeting. Montreal, Canada, 12-16 September 2008.
29. Daddona PE, Matriano JA, Mandema J, Maa Y-F. Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm. Res. 28(1), 159-165 (2011).
30. Jadhav KR, Gambhire MN, Shaikh I, Kadam V, Pisal SS. Nasal drug delivery system - factors affecting and applications. Curr. Drug Ther. 2(1), 27-38 (2007). (Pubitemid 46723136)
31. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J. Pharm. Pharmaceut. Sci. 12(3), 288-311 (2009).
32. Henkin RI. Intranasal insulin: from nose to brain. Nutrition 26(6), 624-633 (2010).
33. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 14, 3754-3779 (2009).
34. Leary AC, Stote RM, Cussen K, O'Brien J, Leary WP, Buckley B. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with Type 1 diabetes: a preliminary study. Diabetes Technol. Ther. 8(1), 81-88 (2006).
35. Leary AC, Dowling M, Cussen K, O'Brien J, Stote RM. Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin™) administered to healthy male volunteers: influence of the nasal cycle. J. Diabetes Sci. Technol. 2(6), 1054-1060 (2008).
36. Henkin RI. Inhaled insulin - intrapulmonary, intranasal, and other routes of administration: mechanisms of action. Nutrition 26(1), 33-39 (2010).
37. Grim M, Carlson BM. Alkaline phosphatase and dipeptidyldipeptidase IV staining of tissue components of skeletal muscle: a comparative study. J. Histochem. Cytochem. 38(12), 1907-1912 (1990). (Pubitemid 20382408)
38. Ryan JW. Peptidase enzymes of the pulmonary vascular surface. Am. J. Physiol. Lung Cell Mol. Biol. 257(2), L53-L60 (1989).
39. Cefalu WT. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 27(1), 239-246 (2004). (Pubitemid 38196739)
40. Siekmeier R, Scheuch G. Systematic treatment by inhalation of macromolecules - principles, problems, and examples. J. Physiol. Pharmacol. 59(Suppl. 6), 53-79 (2008).
41. Rave K, Heise T, Pfützner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with Type 2 diabetes. Diabetes Care 30(9), 2307-2308 (2007). (Pubitemid 47359038)
42. Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with Type 2 diabetes. J. Diabetes Sci. Technol. 2(2), 205-212 (2008).
43. Heinemann L, Heise T. Current status of the development of inhaled insulin. Br. J. Diabetes Vasc. Dis. 4(5), 295-301 (2004). (Pubitemid 39462106)
44. Bergenstal RM, Kapsner PL, Rendell MS et al. Comparative efficacy and safety of AFRESA™ and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Presented at: American Diabetes Association's 69th Scientific Sessions. New Orleans, LA, USA, 5-7 June 2009.
45. Lorber D, Howard CP, Ren H, Rossiter A, Boss AH. Reduced incidence and frequency of hypoglycemia in an integrated analysis from clinical trials of subjects with Type 2 diabetes using prandial inhaled Technosphere® insulin. Presented at: AACE 19th Annual Meeting and Clinical Congress. Boston, MA, USA, 21-25 April 2010.
46. Raskin P, Phillips MD, Rossiter A, Boss AH, Richardson PC. A1C and hypoglycemia in patients with Type 2 diabetes mellitus incorporating prandial inhaled Technosphere insulin into their usual antihyperglycemic regimen vs continuing their usual antihyperglycemic regimen. Presented at: American Diabetes Association's 70th Scientific Sessions. Orlando, FL, USA, 25-29 June 2010.
47. Rosenstock J, Lorber DL, Gnudi L et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for Type 2 diabetes: a multicentre randomised trial. Lancet 375(9733), 2244-2253 (2010).
48. Comulada AL, Renard E, Nakano M et al. Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with Type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. Diabetes Technol. Ther. 11(Suppl. 2), S17-S25 (2009).
49. Garg SK, Mathieu C, Rais N et al. Two-year efficacy and safety of AIR inhaled insulin inpatients with Type 1 diabetes: an open-label randomized controlled trial. Diabetes Technol. Ther. 11(Suppl. 2), S5-S16 (2009).
50. Hollander PA, Krasner A, Klioze S, Schwartz P, Duggan W. Body weight changes associated with insulin therapy. Diabetes Care 30(10), 2508-2510 (2007).
51. Moses RG, Bartley P, Lunt H et al. Treatment safety and efficacy of inhaled insulin (AERx iDMS1) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabetic Med. 26(3), 260-267 (2009).
52. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am. J. Physiol. Endocrinol. Metab. 286(6), E882-E890 (2004). (Pubitemid 38668808)
53. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in Type 2 diabetes: a parallel-group study. Lancet 359(9309), 824-830 (2002). (Pubitemid 34233752)
54. Vilsbøll T, Agersø H, Krarup T, Holst. JJ. Similar elimination rates of glucagon-like peptide-1 in obese Type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88(1), 220-224 (2003). (Pubitemid 36115169)
55. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog. Neurobiol. 92(3), 442-462 (2010).
56. Leone-Bay A, Grant M, Greene S et al. Evaluation of novel particles as an inhalation system for GLP-1. Diabetes Obes. Metab. 11(11), 1050-1059 (2009).
57. Marino MT, Costello D, Baughman R et al. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof of concept studies in healthy normal volunteers and in patients with Type 2 diabetes. Clin. Pharmacol. Ther. 88(2), 243-250 (2010).
58. Vilsbøll T, Toft-Nielsen M-B, Krarup T, Madsbad S, Dinesen B, Hulst JJ. Evaluation of b-cell secretory capacity using glucagon-like peptide-1. Diabetes Care 23(6), 807-812 (2000). (Pubitemid 30414198)
59. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nuclear Med. 48(5), 736-743 (2007). (Pubitemid 47604973)
60. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy males. Am. J. Clin. Nutr. 92(4), 810-817 (2010).
61. Beglinger C, Poller B, Arbit E et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin. Pharmacol. Ther. 84(4), 469-474 (2008).
62. Leone-Bay A. Mimicking endogenous peptide secretion by inhalation. Presented at: 21st American Peptide Symposium Peptides: Breaking Away'. Bloomington, IN, USA, 7-12 June 2009.
63. Leone-Bay A, Baughman R, Smutney C, Kocinsky J. Innovation in drug delivery by inhalation. In: Orally Inhaled and Nasal Drug Delivery: Innovations from Major Delivery System Developers. Furness G (Ed.). ONdrugDelivery Ltd, Newtimber, UK, 4-8 (2010)
64. Tarsa advances OSTORA NDA filing through $28M Series B financing. www.news-medical.net/news/20120317/Tarsa-advances-OSTORA-NDA-filingthrough- 2428M-Series-B-financing.aspx
65. Palmer A. Oppenheimer 22nd Annual Healthcare Conference. www.unigene.com/wp-content/uploads/2011/11/UniGene-1.pdf
66. Atlanta Business Chronicle. $60M later, biotech Altea calls it quits. www.bizjournals.com/atlanta/printedition/2011/12/09/60m-later-biotech- alteacalls-it-quits.html?s=print
67. ClinincalTrials.gov. A study to evaluate the effect of nasal insulin on postprandial glycemic control in Type 2 diabetic patients. http:// clinicaltrials.gov/ct2/show/NCT00624767
68. ClinincalTrials.gov. A study of nasal PYY3-36 and placebo for weight loss in obese subjects. http://clinicaltrials.gov/ct2/show/NCT00537420
69. ClinincalTrials.gov. Study to evaluate effect of intranasal teriparatide on bone mineral density in postmenopausal women with low BMD. http://clinicaltrials.gov/ct2/show/NCT00624481
70. New Hampshire Business Review. CPEX drops Nasulin development. www.nhbr.com/businessnews/statenews/704288-257/cpex-drops-nasulindevelopment. html